Navigation Links
Saliva Test Could Monitor Type 2 Diabetes
Date:1/20/2009

Test might one day replace current blood tests, researchers say

TUESDAY, Jan. 20 (HealthDay News) -- Scientists say they are on the verge of developing a saliva test for monitoring type 2 diabetes, which might someday replace invasive blood tests.

For the first time, researchers from Oregon and India have identified proteins in saliva that appear more frequently in people with diabetes than in non-diabetics. Using these proteins, they are working to develop a test to monitor and perhaps diagnose the condition.

However, Dr. Umesh Masharani, an associate clinical professor of medicine at the University of California, San Francisco, doesn't think this approach is going to replace current blood tests any time soon.

"I think this is an interesting and novel approach," Masharani said. "I do not think this approach will be used in the diagnosis or treatment of diabetes any time in the near future. It is interesting, I think, for research studies in diabetes."

The report was published in the Jan. 2 issue of the Journal of Proteome Research.

For the study, Paturi V. Rao, from the departments of Endocrinology and Metabolism and Medicine at Nizam's Institute of Medical Sciences University in Hyderabad, India, and colleagues analyzed saliva samples from people with and without type 2 diabetes. Their goal was to find proteins associated with the blood sugar disease.

The researchers found 65 proteins that occurred twice as frequently in the people with diabetes than in those without the condition.

Using these proteins, Rao's team hopes to develop a noninvasive test for diabetes screening, detection and monitoring.

Rao's group thinks the pain involved with current diabetes monitoring causes many diabetics to be lax in monitoring their condition. A noninvasive test could make it easier and less painful for patients to keep track of their blood sugar levels.

"As recent studies have shown that early and multi-factorial intervention in diabetes prevents cardiovascular complications and mortality, advances in understanding molecular aspects of preclinical diabetes will further facilitate accurate diagnosis and early intervention," the authors wrote.

Diabetes expert Dr. Charles F. Burant, a professor of internal medicine at the University of Michigan, isn't convinced that a test using proteins in saliva is needed.

"I think it has minimal clinical impact," Burant said. "To be a valid biomarker, a test has to be sensitive and specific. We don't know the value of either for any of the proteins at the present time."

The biggest question is why this is needed, Burant noted. "Diabetes and prediabetes have a valid biomarker -- glucose -- that is the measure of the disease state. Thus, this is interesting biochemistry and raises questions why these changes occur, but the clinical utility is unclear."

More information

For more about type 2 diabetes, visit the American Diabetes Association.



SOURCES: Umesh Masharani, M.D., associate clinical professor, medicine, University of California, San Francisco; Charles F. Burant, M.D., Ph.D., professor, internal medicine, University of Michigan, Ann Arbor; Jan. 2, 2009, Journal of Proteome Research


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. UT Health Science Center researchers decoding saliva to detect breast cancer
2. Salivary diagnostics, the magic mirror to your health ... at your personal computer
3. Melvin receives Salivary Research Award
4. Bi-Coastal Pharmaceutical Corp. Acquires U.S. Marketing Rights to Aquoral(TM) Artificial Saliva Product
5. Bat Saliva-Based Stroke Drug Disappoints in Trial
6. Saliva Test Could Indicate Autism
7. Study provides hope that some transplant patients could live free of antirejection drugs
8. Study provides hope that some transplant patients could live free of anti-rejection drugs
9. HIV denialists spread misinformation online -- consequences could be deadly; and more
10. Virus Could Help Drive Obesity
11. Discovery of sugar sensor in intestine could benefit diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Saliva Test Could Monitor Type 2 Diabetes
(Date:8/17/2017)... ... August 17, 2017 , ... SeQuel Response ... the multichannel growth agency among the fastest-growing private companies in the U.S., putting it ... of companies that have applied to the Inc. 5000 over the years, ...
(Date:8/17/2017)... ... 17, 2017 , ... An August 2 article on NextShark discusses ... largely influenced by the growing popularity of “pretty boys” in both K-Pop and television ... of male appearance are changing not only in the Asian nation, where plastic surgery ...
(Date:8/17/2017)... , ... August 17, 2017 , ... ... The Journey to Healing Through Forgiveness ($15.99, paperback, 9781498497626; $7.99, eBook, 9781498497633) ... to encourage inner healing of memories and achieve forgiveness, through a progressive journey ...
(Date:8/17/2017)... , ... August 17, 2017 , ... Inc. Magazine Unveils ... at No. 132 with Three-Year Sales Growth of 3,004.8% , NEW YORK, August 16, ... Inc. 5000, the most prestigious ranking of the nation's fastest-growing private companies. The list ...
(Date:8/17/2017)... ... , ... Momkus McCluskey Roberts LLC recently announced it was naming ... the firm’s Commercial Litigation and Employment Law groups. , Ms. Parks joined Momkus ... of employment litigation, commercial litigation and business disputes. Her experience includes all aspects of ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... 2, 2017 Fenita J. Caldwell ... a Pinnacle Lifetime Professional in the Field of ... at Turing Pharmaceuticals, AG. Her skills and areas ... building.                ... years of experience as a highly successful sales ...
(Date:8/2/2017)... , Aug. 2, 2017  Life Flight Network and ... The agreement improves patient care and operational efficiency for patients ... Springfield , Cottage Grove , and ... medical transportation. PeaceHealth and Life Flight Network work collaboratively to ... during transport, or when a time sensitive emergency exists. ...
(Date:8/1/2017)...   CerSci Therapeutics , a non-opioid drug development ... has received notice from the National Institute on Drug ... that it has been awarded a Direct-to-Phase II Small ... 2017 with an additional $1,000,000 to follow in 2018. ... of their lead non-opioid drug candidate CT-044 to the ...
Breaking Medicine Technology: